The achievement of two keymilestones in the clinical...

The achievement of two key
milestones in the clinical development
of BNC105 for the treatment of solid
tumours firstly our proposed Phase
II trial in patients with renal cell
cancer in association with the Hoosier
Oncology Group and secondly the
selection of the dose level to be used
in this trial


The initiation of the first clinical trial
of BNC210, Bionomics drug candidate
for the treatment of chronic and
acute forms of anxiety.

Watch out for this stock!!!